Upstream Bio Future Growth
Future criteria checks 2/6
Upstream Bio's earnings are forecast to decline at 20.5% per annum while its annual revenue is expected to grow at 25.4% per year. EPS is expected to grow by 52.3% per annum. Return on equity is forecast to be -34.3% in 3 years.
Key information
-20.5%
Earnings growth rate
52.3%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 25.4% |
| Future return on equity | -34.3% |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -173 | -72 | -130 | 3 |
| 12/31/2025 | 2 | -134 | -53 | -97 | 3 |
| 12/31/2024 | 2 | -81 | -32 | -56 | 4 |
| 9/30/2024 | 2 | -70 | -56 | -56 | N/A |
| 6/30/2024 | 2 | -55 | -47 | -47 | N/A |
| 3/31/2024 | 2 | -47 | -42 | -42 | N/A |
| 12/31/2023 | 2 | -38 | -38 | -38 | N/A |
| 12/31/2022 | 1 | -24 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UPB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: UPB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: UPB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: UPB's revenue (25.4% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: UPB's revenue (25.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UPB is forecast to be unprofitable in 3 years.